Bausch Health Raises 2026 Guidance Again, As Interim CEO Gives Fragmentary Answer On Bausch + Lomb

Thomas Appio, interim CEO of both companies, gave a broken answer on a combination while Bausch Health reported $1.566 billion in revenue.

Share
Bausch Health Raises 2026 Guidance Again, As Interim CEO Gives Fragmentary Answer On Bausch + Lomb

Asked on Bausch Health's third-quarter earnings call Wednesday whether the company might formally combine with Bausch + Lomb, CEO Thomas Appio, who is also interim CEO of Bausch + Lomb, gave an answer that trailed off before reaching a conclusion. The question came as the company reported $1.566 billion in revenue excluding Bausch + Lomb, up 12%, and raised its full-year outlook for the second time this year.

A question left hanging

An analyst from Evercore ISI said it "seems increasingly" that the two companies could come together, "all under one roof," which the analyst noted is technically already the case, and asked Appio to describe the direction of travel.

Appio's reply, in the machine-made transcript, is fragmentary and includes a stray tag for CFO JJ Charron mid-answer. He said "nothing has changed in the past" and spoke of the foundation of "many talented teams," then the answer stopped.

In prepared remarks, Appio listed "Maximize the value of Bausch & Lomb for shareholders" as the fourth of his business priorities, after portfolio performance, organic growth and pipeline building. He said he is "honored and energized" to be Bausch + Lomb's interim CEO and remains "fully committed" to Bausch Health. Brent Saunders left Bausch + Lomb as CEO and director on October 12, and Appio, the board chairman, became interim CEO that day, according to a Yahoo Finance commentary.

Guidance up across the board

Bausch Health is a specialty pharmaceutical and device company, with gastroenterology, hepatology, neurology and dermatology products, and about 88% of Bausch + Lomb, the eye-health business. For the quarter, excluding Bausch + Lomb, adjusted EBITDA was $1.022 billion and adjusted cash flow from operations was $539 million, CFO Charron said. Salix revenue was $831 million, with Xifaxan up 16%.

The company now expects 2026 revenue of $5.525 billion to $5.625 billion, adjusted EBITDA of $3.225 billion to $3.275 billion, and adjusted cash flow from operations of $1.6 billion to $1.675 billion. Net debt fell $521 million in the quarter, and the company has $2 billion of cash.

It plans early redemptions of its 2027 notes, up to $100 million of open-market purchases of its public debt, and a $50 million share buyback aimed at offsetting dilution from management equity awards expected to vest in 2027.

Fourth-quarter drags

Charron said fourth-quarter growth will be hit by a gross-to-net accrual tied to the lower Medicare price for Xifaxan starting January 1, 2027, worth 800 basis points of revenue growth and 1,400 basis points of adjusted EBITDA growth. Normalizing Xifaxan channel inventory could take at least 300 and 500 more, respectively. He put the net 2027 impact at around $400 million to $500 million.

On the call, Chief Medical Officer Jonathan Sade said the late-stage alcohol-associated hepatitis program needs no interim analysis and remains on track toward a goal of approval in 2029.

Appio told analysts business development remains a high priority across hepatology, gastroenterology, dermatology and neuroscience.

Sources

More on Bausch Health

All Bausch Health (BHC) coverage →